RLMD News Alert Relmada Therapeutics Inc. (RLMD) 2.9800 12/16/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Relmada Therapeutics Inc. (RLMD) 2.9800 $RLMD

Relmada Therapeutics hires Christine Silverstein as director of Investor Relations
M2 - Thu Dec 11, 6:17AM CST
Pharmaceutical company Relmada Therapeutics (OtherOTC:RLMD) revealed on Wednesday the election of Christine Silverstein as director of its investor relations.

Relmada Therapeutics Appoints Christine Silverstein as Director of Investor Relations
PR Newswire - Wed Dec 10, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Christine Silverstein as director of investor relations, effective immediately. She will report to Michael Becker, senior vice president of finance and corporate development at Relmada.

Relmada Therapeutics to begin first pharmacokinetic and pharmacodynamic study of d-Methadone for neuropathic pain in Canada
M2 - Wed Dec 03, 7:09AM CST
Pharmaceutical company Relmada Therapeutics (Other OTC:RLMD) reported on Tuesday the receipt of Health Canada's No Objection Letter (NOL) to start the first pharmacokinetic and pharmacodynamic study of its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain, d-Methadone.

Relmada Therapeutics Nominated for Buzz of BIO Contest at the 2015 BIO CEO & Investor Conference
PR Newswire - Wed Dec 03, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, is pleased to participate in the Buzz of BIO Contest in connection with the 2015 BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference features leading private and emerging public companies and will take place February 9-10, 2015 at the Waldorf Astoria in New York, NY.

Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study of d-Methadone
PR Newswire - Tue Dec 02, 7:30AM CST
Novel Product Virtually Devoid of Opioid Activity Being Studied in Neuropathic Pain.

Relmada Therapeutics To Present At LD MICRO Conference
PR Newswire - Mon Nov 24, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, chief executive officer, is scheduled to present at the LD MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014. The conference will be held at the Luxe Sunset Bel Air Hotel, which is located at 11461 Sunset Boulevard in Los Angeles, California.

Relmada Therapeutics hires Michael Becker as SVP of finance and corporate development to broaden and strengthen its senior leadership team
M2 - Wed Nov 05, 6:31AM CST
Biopharmaceutical company Relmada Therapeutics (OtherOTC:RLMD) disclosed on Tuesday the election of Michael D. Becker as senior vice president of its finance and corporate development with immediate effect.

Relmada Therapeutics Appoints Michael Becker As Senior Vice President Of Finance And Corporate Development
PR Newswire - Tue Nov 04, 7:00AM CST
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Michael D. Becker as senior vice president of finance and corporate development, effective immediately.

Relmada Therapeutics Adds $15 Million in Capital to Expedite Development of Pain Treatment Drugs
Marketwired - Wed Oct 29, 8:08AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with four novel pain treatment drugs currently under development in its pipeline, received a healthy injection of more than $15 million in capital last week that will assist the company in the advancement of its work to bring those products to the largest drug prescription market in the world - the treatment of pain.

Relmada Therapeutics Reinforces Balance Sheet With $15.2 Million From Exercise Of Warrants
PR Newswire - Thu Oct 16, 7:00AM CDT
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the issuance of approximately 10.1 million of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with private placements that closed in May and June 2014. The warrants were exercised at $1.50 per share, resulting in gross proceeds of approximately $15.2M for the Company.

New Report Initiates Coverage on New Public Biopharmaceutical Company, Relmada Therapeutics, Inc.
Marketwired - Thu Oct 09, 8:16AM CDT
After careful analysis, Stock Market Media Group (SMMG), a research and content development IR firm, announces that it has initiated coverage on Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with 4 novel drugs currently in its pipeline under development. In a new Report, SMMG examines the company's unique drug development strategy, its pipeline of drugs for the treatment of pain, the multi-billion dollar market in which the biotech's products will compete, and both the impressive management team and Scientific Advisory Board that will lead the firm into the future.

Relmada Therapeutics names Julie J. Chen as director of Finance and Operations to strengthen financial and business operations
M2 - Fri Oct 03, 4:35AM CDT
Pharmaceutical company Relmada Therapeutics (OTC BB :RLMD) reported on Thursday the addition of Julie J. Chen as director of its Finance and Operations.

Relmada Therapeutics Appoints Julie J. Chen As Director of Finance and Operations
PR Newswire - Thu Oct 02, 7:15AM CDT
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Julie J. Chen as its Director of Finance and Operations.

Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development
PR Newswire - Thu Sep 18, 6:45AM CDT
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Mr. Christopher W. James to the position of Senior Director of Clinical Development.

Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER
PR Newswire - Tue Sep 16, 6:45AM CDT
Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has entered into an agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in a series of animal studies for levorphanol, the active ingredient of LevoCap ER, a new tamper-resistant, extended release form of levorphanol. Gavril Pasternak, MD, PhD, of MSKCC is the lead investigator for these studies.

Relmada Announces The Filing Of Clinical Trial Application In Canada For d-methadone
PR Newswire - Wed Sep 10, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCBB: RLMD) ("Relmada" or the "Company" , a clinical stage company developing novel therapies for the treatment of chronic pain, today announced that it has filed a Clinical Trial Application (CTA) with Heath Canada to conduct 2 pharmacokinetic studies with d-methadone, its NMDA receptor antagonist for neuropathic pain. Health Canada has accepted the application that is now under review.

Relmada Therapeutics, Inc. Provides Its First Corporate Update as a Public Company
PR Newswire - Tue Sep 09, 7:15AM CDT
Relmada Therapeutics, Inc., (OTCBB: RLMD), a Nevada corporation (the "Company" developing novel therapies for the treatment of chronic pain, today announced that is has filed its Form 10-K with the SEC, showing the Company's significant strides in 2014. The Company has made significant progress scientifically, financially and structurally in the implementation of its business strategy and is pleased to provide its first corporate update as a public company.

Opium (Opioid) Addiction - Pipeline Review, H2 2014 - 19 Drug Profiles from 13 Companies
M2 - Tue Sep 09, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76t4hq/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alkermes Plc - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - INSYS Therapeutics, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - AllTranz, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - TA-CD - buprenorphine hydrochloride - RBP-6300 - Cannabidiol - OMS-405 - MAL - samidorphan - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Vaccine for Opium Addiction - Cannabidiol - FP-004 - methadone IR - buprenorphine hydrochloride - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - naltrexone For more information visit http://www.researchandmarkets.com/research/76...ium_opioid
INSY: 41.31 (+0.23), CPRX: 2.88 (+0.02), ALKS: 52.34 (-1.08), ACUR: 0.48 (unch), OMER: 20.51 (-0.62)

Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
PR Newswire - Wed Sep 03, 6:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company" , today announced it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 17

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
AIC Hotel Group's 11 Awards Test Resort Market Reach

Updated Category News Views 89

Eleven Trophies, Four Properties, One Useful Signal Hospitality awards can be a lot of polished brass and very little cash flow, but this batch is substantial enough to deserve a hard look. AIC Hotel Group collected 11 honors spanning Condé Nast Traveler's 2026 Readers' Choice Awards, Travel Weekly's 2026 Magellan Awards, and Good Housekeeping's 2027 Travel Awards. The...

Continue Reading
Saban Center Partnership Gives Health Learning a Lift

Updated Category News Views 45

A dinosaur race may sound like pure kid bait, but the underlying idea is sturdier than that. Cardiac Solutions and the Seale family are backing an interactive health-and-performance exhibit at Tuscaloosa’s planned Saban Center, a project intended to turn questions about movement, fitness, heart rate and oxygen levels into something children can actually touch, test and...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 138

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
FLX Opens a New Door to Pre-IPO Deal Flow for Advisors

Updated Category News Views 126

Private-market chatter has been leaking past the velvet rope for years, and advisors are sick of learning about it after a client already has a pitch deck in hand. FLX Networks is responding to that irritation by letting its eligible advisor and wealth-management members review select pre-IPO opportunities shared by other members. Announced November 19, 2026, the move is...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 164

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline

Updated Category News Views 110

A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...

Continue Reading
CMA Wins Spotlight Greenberg Traurig’s Music Bench

Updated Category News Views 81

Four trophies on one awards night can say plenty about the machinery behind a music career, even if nobody should confuse a CMA acceptance speech with a balance-sheet event. Greenberg Traurig’s entertainment practice is celebrating client wins at the 60th annual CMA Awards, held Nov. 18, 2026: three honors tied to Miranda Lambert and one for Brooks & Dunn. For investors...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 47

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 118

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading

Top 5 Most Recently Viewed Articles

Eastman Chemical’s Stock Surge Marks a Turning Point for Investors

Updated Category News Views 82

Eastman Chemical's Stock Hits New Heights Eastman Chemical Company (NYSE: EMN) has recently reached an impressive milestone, with its stock price climbing to a 52-week high of $107.14. This significant price point reflects growing investor confidence and a positive market outlook for the company. With a remarkable 34.6% increase over the past year, Eastman Chemical has...

Continue Reading
BOS Expands Automation Solutions with New System Orders

Updated Category News Views 270

BOS Secures New Orders for Robotic Solutions BOS Better Online Solutions Ltd. (NASDAQ: BOSC), renowned for its expertise in supply chain technologies, has recently announced a significant milestone. The company secured orders for two innovative robotic packing and palletizing systems aimed at enhancing efficiency in food manufacturing. Details of the New Orders These new...

Continue Reading
Amazon's Cloud and AI Strategy Set to Shape Future Growth

Updated Category News Views 260

Overview Amazon.com, Inc. (NASDAQ: AMZN) plays a crucial role in the realms of e-commerce, cloud computing, digital streaming, and artificial intelligence. Recent analyses from respected financial institutions provide a thorough insight into Amazon's market performance, strategic initiatives, and its future outlook. This article brings together these evaluations, zeroing...

Continue Reading
WTW's Strategic Acquisitions: A Leap into the Future of Insurance

Updated Category News Views 211

WTW Expands Through Innovative Acquisitions Willis Towers Watson Public Ltd., known as WTW, is making headlines with its ambitious strategy to enhance its technology-enabled insurance and workplace benefits services. By announcing two consequential acquisitions, WTW aims to broaden its reach in the middle market while modernizing its client interactions significantly....

Continue Reading
Genmab's Share Buy-Back Program: Recent Transaction Details

Updated Category News Views 173

Introduction to Genmab Genmab A/S is a pioneering biotechnology company based in Copenhagen, Denmark, dedicated to improving the lives of patients through innovative antibody therapies. Founded in 1999, Genmab has continuously worked on developing groundbreaking antibody technology platforms, aiming to advance treatment for serious diseases such as cancer. Share Buy-Back...

Continue Reading